Victory Capital Management Inc. Has $89,000 Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Victory Capital Management Inc. raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 111.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,097 shares of the biopharmaceutical company’s stock after acquiring an additional 18,532 shares during the quarter. Victory Capital Management Inc. owned approximately 0.07% of Puma Biotechnology worth $89,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. raised its stake in shares of Puma Biotechnology by 98.5% in the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares during the last quarter. Affinity Asset Advisors LLC bought a new stake in Puma Biotechnology during the 2nd quarter worth approximately $815,000. Frazier Life Sciences Management L.P. increased its holdings in Puma Biotechnology by 8.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after purchasing an additional 246,264 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Puma Biotechnology in the 3rd quarter valued at $627,000. Finally, Great Point Partners LLC boosted its stake in Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Stock Performance

PBYI stock opened at $3.39 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a twelve month low of $2.22 and a twelve month high of $7.73. The business’s fifty day moving average is $2.84 and its 200-day moving average is $3.11. The company has a market cap of $166.42 million, a P/E ratio of 7.06 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period in the prior year, the business posted $0.12 EPS. Equities research analysts forecast that Puma Biotechnology, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PBYI shares. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 20th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.